CO6721059A2 - Composiciones farmacéuticas de tenecteplasa - Google Patents

Composiciones farmacéuticas de tenecteplasa

Info

Publication number
CO6721059A2
CO6721059A2 CO13159374A CO13159374A CO6721059A2 CO 6721059 A2 CO6721059 A2 CO 6721059A2 CO 13159374 A CO13159374 A CO 13159374A CO 13159374 A CO13159374 A CO 13159374A CO 6721059 A2 CO6721059 A2 CO 6721059A2
Authority
CO
Colombia
Prior art keywords
tenecteplase
pharmaceutical compositions
compositions
tnk
treatment
Prior art date
Application number
CO13159374A
Other languages
English (en)
Spanish (es)
Inventor
Maheshwari Kumar Mishra
Pritiranjan Bhandari
Sanjay Singh
Original Assignee
Gennova Biopharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46313261&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6721059(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gennova Biopharmaceuticals Ltd filed Critical Gennova Biopharmaceuticals Ltd
Publication of CO6721059A2 publication Critical patent/CO6721059A2/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482Serine endopeptidases (3.4.21)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21Serine endopeptidases (3.4.21)
    • C12Y304/21068Tissue plasminogen activator (3.4.21.68), i.e. tPA

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CO13159374A 2010-12-23 2013-07-05 Composiciones farmacéuticas de tenecteplasa CO6721059A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN3516MU2010 2010-12-23

Publications (1)

Publication Number Publication Date
CO6721059A2 true CO6721059A2 (es) 2013-07-31

Family

ID=46313261

Family Applications (1)

Application Number Title Priority Date Filing Date
CO13159374A CO6721059A2 (es) 2010-12-23 2013-07-05 Composiciones farmacéuticas de tenecteplasa

Country Status (17)

Country Link
US (2) US20130323227A1 (enExample)
EP (1) EP2654770B1 (enExample)
JP (1) JP6375112B2 (enExample)
CN (1) CN103391785A (enExample)
AU (1) AU2011346515B2 (enExample)
BR (1) BR112013015914B1 (enExample)
CO (1) CO6721059A2 (enExample)
DK (1) DK2654770T3 (enExample)
EA (1) EA026017B1 (enExample)
ES (1) ES2687850T3 (enExample)
LT (1) LT2654770T (enExample)
MX (1) MX356199B (enExample)
MY (1) MY171723A (enExample)
NZ (1) NZ611706A (enExample)
PL (1) PL2654770T3 (enExample)
PT (1) PT2654770T (enExample)
WO (1) WO2012085933A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX383595B (es) * 2014-10-21 2025-03-14 Gennova Biopharmaceuticals Ltd Proceso novedoso de purificacion para el aislamiento y produccion comercial de tnk-tpa recombinante (tenecteplasa)
EP3624832B1 (en) * 2017-05-16 2025-08-20 Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical compositions for the treatment of acute ischemic stroke
WO2019229764A1 (en) * 2018-06-01 2019-12-05 Gennova Biopharmaceuticals Limited Process for production of recombinant tnk-tpa by packed-bed perfusion system
CN114984197A (zh) * 2022-07-01 2022-09-02 江苏丰华生物制药有限公司 替奈普酶在制备用于治疗急性缺血性卒中的药物组合物中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10230752A1 (de) * 2002-07-09 2004-01-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittelkompositionen auf der Basis von Magnesiumsalzen und Fibrinolytika
US20070014779A1 (en) * 2002-11-14 2007-01-18 Genentech, Inc. Plasminogen activator variant formulations
WO2006094120A2 (en) * 2005-03-02 2006-09-08 The Regents Of The University Of California Treatment for embolic stroke
US20070166299A1 (en) * 2005-03-02 2007-07-19 The Regents Of The University Of California Treatment for embolic stroke
TWI439282B (zh) * 2006-08-29 2014-06-01 Genentech Inc 以血栓溶解劑治療中風之方法
CA2668347C (en) * 2006-11-07 2017-06-20 Genentech, Inc. Tissue plasminogen activator variant uses
EP2014760A1 (en) * 2007-06-13 2009-01-14 CMC Biopharmaceuticals A/S A method for producing a biopolymer (e.g. polypeptide) in a continuous fermentation process

Also Published As

Publication number Publication date
EA201300746A1 (ru) 2013-11-29
WO2012085933A1 (en) 2012-06-28
AU2011346515A1 (en) 2013-07-04
NZ611706A (en) 2015-04-24
MX2013007381A (es) 2013-08-29
PT2654770T (pt) 2018-10-19
EP2654770A4 (en) 2014-05-21
US20130323227A1 (en) 2013-12-05
ES2687850T3 (es) 2018-10-29
EP2654770A1 (en) 2013-10-30
JP2014502608A (ja) 2014-02-03
LT2654770T (lt) 2018-09-10
AU2011346515B2 (en) 2017-01-19
MY171723A (en) 2019-10-24
MX356199B (es) 2018-05-18
BR112013015914B1 (pt) 2021-06-08
JP6375112B2 (ja) 2018-08-15
BR112013015914A2 (pt) 2016-10-11
EA026017B1 (ru) 2017-02-28
CN103391785A (zh) 2013-11-13
US9943575B2 (en) 2018-04-17
EP2654770B1 (en) 2018-07-11
US20160310580A1 (en) 2016-10-27
DK2654770T3 (en) 2018-10-29
PL2654770T3 (pl) 2018-12-31

Similar Documents

Publication Publication Date Title
PE20181155A1 (es) Composiciones que comprenden cepas bacterianas
ECSP15048555A (es) Heterociclos bicíclicos como inhibidores de fgfr
CO7240375A2 (es) Compuestos tricíclicos sustituidos como inhibidores del fgfr
AR125920A2 (es) Composiciones que comprenden vortioxetina y donepezil
CL2013003019A1 (es) Compuestos derivados de benzotiazol; composicion farmaceutica que los comprende; y su uso en el tratamiento del vih.
CL2016001933A1 (es) Compuestos derivados de macrociclos, inhibidores del factor xia composición farmacéutica que los comprende y su uso en el tratamiento yo profilaxis de una enfermedad tromboembolica. pct
GT201400147A (es) Pirimidinas y triazinas fusionadas sustituidas y su uso
AR089155A1 (es) Unidad de procesamiento de isomerizacion y transalquilacion de xileno combinada
MX336741B (es) Composiciones farmaceuticas de moduladores de c-met.
AR093756A1 (es) Composiciones que comprenden polimeros cationicos hidrofobamente modificados
MX2015010312A (es) Metodos para tratamiento del melanoma.
UY34201A (es) Compuestos de azaindol y métodos para el tratamiento de vih.
MX2016010216A (es) Composiciones farmaceuticas solidas de antagonistas de los receptores de androgenos.
UY36075A (es) Derivados de tubulisina
MX2016016301A (es) Procesos de siembra en serie y usos de los mismos.
BR112015021880A2 (pt) rearranjo de vírus influenza b
UY37917A (es) Nuevos enantiómeros de una serie de compuestos antivirales
RU2011135537A (ru) Штамм enterococcus hirae, используемый при производстве кисломолочных продуктов
CR20150603A (es) Metaloproteinasa de la matriz y usos del mismo
CO2017007899A2 (es) Composición biodegradable resistente a la humedad
MX389026B (es) Una composicion farmaceutica y el uso de la misma.
MX347570B (es) Compuestos triciclicos, composiciones que los comprenden y usos de los mismos.
MX2016006591A (es) Agentes anticancerosos y sus preparaciones.
CO6721059A2 (es) Composiciones farmacéuticas de tenecteplasa
MX2017002323A (es) Variantes de desintegrina y usos farmaceuticos de las mismas.